Table III.
Percentage of patients reaching efficacy endpoints by study phase and treatment group.
| Acute phase | Delayed phase | |||
|---|---|---|---|---|
| Endpoint | Standard regimen group, % (n=54) | Aprepitant regimen group, % (n=59) | Standard regimen group,% (n=54) | Aprepitant regimen group,% (n=59) |
| Complete response | 94.4 | 94.9 | 79.6 | 79.7 |
| Complete protection | 94.4 | 93.2 | 79.6 | 78.0 |
| No vomiting | 94.4 | 98.3 | 81.5 | 86.4 |
| No nausea | 96.3 | 89.8 | 68.5 | 64.4 |
| No significant nauseaa | 100.0 | 98.3 | 88.9 | 91.3 |
a
Nausea score 0 and 1. There were no statistically significant differences between the treatment groups for any endpoints.